Could pressure for COVID-19 drugs lead the FDA to lower its standards?

Leigh Turner, PhD has worked tirelessly to uncover ethical issues in stem cell therapy marketing and regulation. In this piece by The Conversation, Turner examines whether the U.S. FDA is lowering its regulatory standards & being insufficiently transparent as it expedites review of drugs & other products intended to treat individuals with COVID-19 or prevent the spread of SARS-CoV-2.